FL-115 is under clinical development by Suzhou Forlong Biotechnology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FL-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FL-115 overview
FL-115 is under the development for the treatment of solid tumor which include non-small cell lung cancer and non-muscle invasive bladder cancer . The therapeutic candidate is interleukin 15 (IL15) fusion protein administered through parenteral and intravenous and parenteral route and acts by targeting IL15 receptor subunit alpha (IL15RA). It is being developed based on F-body technology, which overcomes the short half-life of recombinant IL15, and has a small molecular weight, strong penetration into solid tumors.
Suzhou Forlong Biotechnology overview
Suzhou Forlong Biotechnology, a biotechnology company that focused on innovative biological drug development, protein drugs such as cytokines, integrated synthetic immunology system and biological molecular evolution services. Forlong Biotechnology is headquartered in Suzhou, Jiangsu, China.
For a complete picture of FL-115’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
